Indevus closer to marketing authorization for Ventas in Europe

July 2007
PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p16
Market Research Report
The article reports that Indevus Pharmaceuticals Inc. has filed for Mutual Recognition Procedure (MRP) to obtain marketing authorization for Ventas, a subcutaneous implant for the treatment of prostate cancer, in various European countries. Chief executive officer (CEO) Glenn Cooper states the company intends to complete the process for marketing approval and to begin MRP for the remaining countries in the European Union.


Related Articles

  • GPC Biotech to withdraw marketing application for satraplatin.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p11 

    The article reports on the plan of GPC Biotech AG to withdraw the marketing authorization application for satraplatin due to its failure to treat hormone-refractory prostate cancer in Europe. The initiative was based on the disapproval of the Committee for Medicinal Products for Human Use of the...

  • Dendreon CEO Not Happy With Sales of Provenge. Winter, Peter // BioWorld Today;8/1/2012, Vol. 23 Issue 148, p1 

    The article reports on the dissatisfaction of Dendreon Corp. chief executive officer (CEO) John Johnson with the commercial performance of the advanced prostate cancer drug Provenge. A net product revenue for the quarter of 80 million U.S. dollars was posted by the company. A strategic...

  • PLAYING THE WAITING GAME. Barrett, Jennifer // Newsweek;5/23/2005, Vol. 145 Issue 21, p79 

    Reports two studies on prostate cancer. A 10-year analysis of Scandinavian men, which was published in the New England Journal of Medicine, suggesting surgery lowers death rates; Research published in the Journal of the American Medical Association suggesting men with low Gleason scores can...

  • Cancer survivor facing new battle at NeoPharm. Chase, Brett // Crain's Chicago Business;8/15/2005, Vol. 28 Issue 33, p2 

    The article focuses on Ronald G. Eidell who beat cancer, survived a boardroom brawl at NeoPharm Inc. and emerged as the biotech company's interim CEO. After his own short battle with prostate cancer, Eidell is determined to get NeoPharm's brain cancer treatment approved for sale. And though he...

  • Indevus Cutting Staff After Formal Approvable Letter.  // BioWorld Today;7/1/2008, Vol. 19 Issue 127, p2 

    The article reports that Indevus Pharmaceuticals has received an official approval letter from the U.S. Food and Drug Administration (FDA) for testosterone Nebido, and has launched a series of cost-cutting measures, including a 12 percent headcount reduction. According to Glenn Cooper, chief...

  • Dendreon: prostate cancer vaccine edges closer to the market.  // PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p12 

    The article focuses on the foreseen performance of prostate cancer drug Provenge from Dendreon Corp. in the U.S. market. Though the company is still seeking for the drug's marketing approval, the author foresees that its introduction to the market will be welcomed enthusiastically. A positive...

  • Indevus: FDA Letter Declares Cancer Therapy 'Approvable'. Osborne, Randall // BioWorld Today;8/20/2007, Vol. 18 Issue 161, p1 

    The article reports on the approval of the bladder-cancer drug Valstar by the U.S. Food and Drug Administration (FDA). According to the author, the approval of Valstar leaves Sanctura XR from Indevus Pharmaceuticals Inc. on track to return to the market in late 2007 or early 2008. Indevus...

  • Indevus Pharmaceuticals: Valstar reintroduced into bladder cancer market.  // PharmaWatch: Monthly Review;Apr2009, Vol. 8 Issue 4, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the reintroduction of Indevus Pharmaceuticals Inc.'s Valstar drug in the bladder cancer market. The reintroduction of the drug will provide a treatment option for underserved Bacillus Calmette-Guerin...

  • Prostvac Improves Prostate Cancer Survival.  // Bioworld Week;10/13/2008, Vol. 16 Issue 41, p3 

    The article focuses on a study which shows that therapeutic prostate cancer vaccine Prostvac improves overall survival by 8.5 months in men with advanced disease. According to Bavarian Nordic A/S chief executive officer Anders Hedegaard, Prostvac does not require complex individualized therapy....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics